FDA Panel To Weigh Animal, Adult Human Data For Initiation Of RSV Vaccine Trials In Infants
Executive Summary
Sponsors have been increasingly developing vaccine candidates for the respiratory syncytial virus with an unmet need existing for infants; the advisory committee will evaluate FDA's proposed approach for developing candidates in the target population.
You may also be interested in...
Regeneron Phase III Stumble Shows RSV Market Is No Child's Play
Failure of Regeneron's anti-RSV antibody suptavumab (REGN2222) comes at a tough time for the company, as some marketed products disappoint and a long-time alliance with Sanofi comes to an end.
RSV Vaccines Need Multiple Animal Models Before Infant Testing, Panel Says
US FDA's advisors want data from three animal models – not just the cotton rats that Janssen was hoping for – before candidate vaccines are tested in healthy infants.
Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine
Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.